PROACT 3: Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The goal of this clinical trial is to evaluate whether disclosure of a non-high polygenic risk score for coronary artery disease (CAD PRS) is non-inferior to standard of care in maintaining cardiovascular health over one year among adults aged 40-75 years without cardiovascular disease and not on statins.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 75
Healthy Volunteers: f
View:
• Current age 40-75 years
• Established primary care at Mass General Brigham with at least one visit in the last 2 years
Locations
United States
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Contact Information
Primary
Roukoz Karam, MD
proact@mgb.org
6174121147
Time Frame
Start Date: 2025-10-15
Estimated Completion Date: 2027-08-15
Participants
Target number of participants: 400
Treatments
Experimental: Immediate Disclosure
Participants are randomized to receive their non-high CAD PRS immediately after genotyping.
Active_comparator: Deferred Disclosure
Participants are randomized to have their non-high CAD PRS withheld for 12 months before receiving their result after the follow up period.
Related Therapeutic Areas
Sponsors
Leads: Massachusetts General Hospital
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)